myelodysplastic syndromes (MDS) | Page 2 | Aplastic Anemia & MDS International Foundation

myelodysplastic syndromes (MDS)

COaching and Prehabilitation: Evaluation of an Early Multidisciplinary Approach in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome (COHABILIT)

This phase II study aims to evaluate the graft-related mortality rate after the initiation of a multidisciplinary prehabilitation program.

Patients will be included within 10 days after the initiation of their treatment. The prehabilitation will consist in a patient-tailored program based on: adapted physical activity, nutritional support and coaching.

SNS-301 Monotherapy in High Risk MDS and CMML

This phase 2, open-label, multi-center trial to evaluate the safety, immunogenicity and preliminary clinical efficacy of intradermally-delivered SNS-301 delivered using the 3M® hollow microstructured transdermal system (hMTS) device in patients with ASPH+ high risk myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). The trial population consists of high risk ≥ Intermediate Risk-3 (IR-3) MDS and CMML-2.

Early Palliative Care for Patients With Haematological Malignancies (CALVI)

Patients suffering from haematological disease present symptoms of discomfort and currently benefit from palliative care skills only for the management of their end-of-life. However, in medical oncology, more and more studies tend to demonstrate the benefit on the quality of life of an early collaboration between the two specialties.

Investigator did the hypothesis that early integration of palliative care with conventional haematological care could decrease discomfort symptoms and add a real benefit on the patients' quality of life .